Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $34-Report Released on 13th Nov 2023
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Sandy Draper has maintained a Hold rating on Evolent Health (NYSE:EVH) and reduced the price target from $36 to $34 as reported on November 13, 2023.
November 14, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities maintains a Hold rating on Evolent Health and lowers the price target from $36 to $34.
The reduction in price target by Truist Securities could lead to a negative perception among investors, potentially causing a short-term dip in Evolent Health's stock price. However, since the rating remains a Hold, the impact may not be significantly bearish.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100